These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37993569)

  • 1. The analysis of the effect of the COVID-19 pandemic on patients with hereditary angioedema type I and type II.
    Szilágyi D; Horváth HR; Andrási N; Kempler MS; Balla Z; Farkas H
    Sci Rep; 2023 Nov; 13(1):20446. PubMed ID: 37993569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life among children with hereditary angioedema.
    Engel-Yeger B; Farkas H; Kivity S; Veszeli N; Kőhalmi KV; Kessel A
    Pediatr Allergy Immunol; 2017 Jun; 28(4):370-376. PubMed ID: 28258590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of COVID-19 on hereditary angioedema activity and quality of life.
    Can Bostan O; Tuncay G; Damadoglu E; Karakaya G; Kalyoncu AF
    Allergy Asthma Proc; 2021 Sep; 42(5):403-408. PubMed ID: 34474710
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
    Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
    Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HAE patient self-sampling for biomarker establishment.
    Förster TM; Magerl M; Maurer M; Zülbahar S; Zielke S; Inhaber N; Crocetta D; Rolfs A; Skrahina V
    Orphanet J Rare Dis; 2021 Sep; 16(1):399. PubMed ID: 34583739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency.
    Andrási N; Veszeli N; Holdonner Á; Temesszentandrási G; Kőhalmi KV; Varga L; Farkas H
    Int Immunopharmacol; 2020 Mar; 80():106216. PubMed ID: 31982824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
    Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
    Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.
    Kőhalmi KV; Veszeli N; Cervenak L; Varga L; Farkas H
    Immunol Lett; 2017 Sep; 189():90-93. PubMed ID: 28577900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for the long-term prevention of hereditary angioedema attacks.
    Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema-A Long-Term Survey.
    Farkas H; Kőhalmi KV; Visy B; Veszeli N; Varga L
    J Allergy Clin Immunol Pract; 2020; 8(7):2379-2383. PubMed ID: 32198128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications.
    Veronez CL; Christiansen SC; Smith TD; Riedl MA; Zuraw BL
    Allergy Asthma Proc; 2021 Nov; 42(6):506-514. PubMed ID: 34871158
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.
    Zanichelli A; Azin GM; Cristina F; Vacchini R; Caballero T
    Orphanet J Rare Dis; 2018 Apr; 13(1):51. PubMed ID: 29631595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency.
    Jacobs J; Neeno T
    Postgrad Med; 2021 Aug; 133(6):639-650. PubMed ID: 33993830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Vasoregulatory Aspects of Hereditary Angioedema: the Role of Arginine Vasopressin, Adrenomedullin and Endothelin-1.
    Kajdácsi E; Jani PK; Csuka D; Varga L; Prohászka Z; Farkas H; Cervenak L
    J Clin Immunol; 2016 Feb; 36(2):160-70. PubMed ID: 26873707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
    Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
    J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
    Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
    Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
    Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.
    Reshef A; Grivcheva-Panovska V; Kessel A; Kivity S; Klimaszewska-Rembiasz M; Moldovan D; Farkas H; Gutova V; Fritz S; Relan A; Giannetti B; Magerl M
    Pediatr Allergy Immunol; 2019 Aug; 30(5):562-568. PubMed ID: 30993784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of anxiety, stress and depression related to COVID-19 pandemic on the course of hereditary angioedema with C1-inhibitor deficiency.
    Eyice Karabacak D; Demir S; Yeğit OO; Can A; Terzioğlu K; Ünal D; Olgaç M; Coşkun R; Çolakoğlu B; Büyüköztürk S; Gelincik A
    Allergy; 2021 Aug; 76(8):2535-2543. PubMed ID: 33650198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema.
    Henry Li H; Riedl M; Kashkin J
    Clin Rev Allergy Immunol; 2019 Apr; 56(2):207-218. PubMed ID: 29909591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.